

Latest Articles


Immune Pathways Driving T Cell Inflammation in Atopic Dermatitis
Atopic dermatitis (AD) is a complex, biologically heterogeneous disease defined by contributions from multiple distinct inflammatory pathways.1,2 In addition to the well characterized role of type 2 inflammation (and Th2 cells) in the development of atopic dermatitis, the Th17, Th22 and Th1 immune axes also contribute to inflammation caused by T cell dysregulation in AD.1,3 T cell inflammation in atopic dermatitis involves a broad immune response, where cytokines are part of a larger T-cell mediated cycle of immune imbalance.2,3

Gaucher Disease Therapy and Management

Gaucher Disease Pathophysiology

Gaucher Disease Genetics and Inheritance

The Role of OX40L/OX40R in Atopic Dermatitis (AD)
Atopic dermatitis (AD) is a chronic inflammatory heterogenous skin condition marked by immune dysregulation and impaired skin barrier function.1,2 For healthcare professionals seeking to understand the immunologic drivers of AD, the OX40L signaling axis has emerged as a key pathway involved in T-cell activation and chronic inflammation.2,3

Systemic and Long-Term Atopic Dermatitis (AD) Treatment
Atopic dermatitis (AD) is a chronic inflammatory condition caused by complex underlying pathophysiology, driven by genetic, immunologic and environmental factors and triggers that collectively disrupt the epidermis.1-3 Despite the range of treatment options available, patients continue to experience fluctuations in disease activity due to the heterogeneity of AD.4-6 There remains an unmet need to develop a deeper understanding of the diverse immune dysregulation profiles found in patients with AD and determine optimal treatment on a more personalized basis.4,6

Understanding Type 2 and Non-Type 2 Inflammation in Atopic Dermatitis
Atopic dermatitis (AD) is a heterogenous disease defined by contributions from multiple distinct inflammatory pathways.1 Although type 2 inflammation‘s role in AD pathogenesis is well-characterized, other non-type 2 T cell-mediated pathways also play a role in AD chronicity.1,2 For healthcare professionals seeking to understand the diversity of immune signatures in their AD patients, looking beyond Th2 cytokines is essential.1

Understanding the Burden of Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis (AD) is a chronic, immune-mediated inflammatory disease that often begins in early infancy and persists into adulthood.1-3 While symptoms such as the intense itch that disrupts the lives of patients are well known, AD also imposes a profound chronic ‘hidden burden’ that extends far beyond visible skin lesions, significantly impairing patients' mental health, relationships, and daily productivity.1-11 This burden can be compounded by the treatment regimens themselves, which can be time-consuming, economically straining, and limited by low patient satisfaction and patient phobias of treatments and their side effects.12-14
MAT-US-2405607-v1.0-06/2024